Skip to main content

Table 1 Molecular mechanism of xenon

From: Update of the organoprotective properties of xenon and argon: from bench to beside

Xenon

Author

Effects revealed in human

Effects revealed in in vivo

Effects revealed in in vitro

Organprotection

Yakamura and Harris [31]

  

Non-competitive blockade of NMDA receptors and nACH (N-acetyl-choline receptors nACH)

 

Li et al. [32]

  

mitoKATPchannel

Heart

Gruss et al. [33]

 

Activation of two-pore-domain K+channel (TREK-1)

 

Brain

Ma et al. [34]

 

Hypoxia inducible factor 1α↑ EPO ↑, VEGF↑

mTOR expression↑

 

Renal

Zhao et al. [35]

  

IGF-1↑, HIF 1α↑, NF-κB↓

Renal

Dinse et al. [36]

  

Blocks AMPA. receptor & kainate receptors

Brain

Bantel et al. [37]

  

KATP – Opener

Brain

Weber et al. [38], Weber et al. [39], Pravdic et al. [40]

 

Protein kinase C (PKC)-ε, EKR1/2

P38MAPK, HSP 27, JNK

 

Heart

Luo et al. [41]

  

PI3K Signaling

Brain

Banks et al. [42],

  

Competitive NMDA receptor inhibition

Brain

Harris et al. [43],

  

Competitive NMDA receptor inhibition

Activation of TREK-1 channels

Brain

Franks et al. [44]

  

Inhibition of NMDA receptor

Brain

  1. ↑ upregulation; ↓ downregulation; ≈ no changes, blockade; AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolole propionate, kainate; Bcl-2 B cell lymphoma 2; GABAA receptor gamma-aminobutyric acid A receptor; LPS lipopolysaccharide; ERK1/2 extracellular signal-regulated kinases 1/2; MEK1/2 = MAPKK mitogen-activated protein kinase; mTOR mammalian target of rapamycin; Nrf2 nuclear factor (erythroid-derived 2)-like 3; TLR Toll-like receptor; NF-κB nuclear factor “kappa-light-chain-enhancer” of activated B cells